Unaudited Standalone Financial Results for Quarter ended 30th September, 2026 along with Auditors limited review report.

Date: 9th November, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai-400051 Scrip Code: 540937 Symbol: MEDICO Dear Sir/Madam, Re.: Outcome of Board Meeting held today Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations”) Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 9th November, 2026 has, inter alia considered and approved the following: 1. Unaudited Standalone Financial Results for the quarter ended 30th September 2026 alongwith Auditors’ Limited Review Report thereon; 2. Appointment of M/s V. J. Talati & Co. as the Cost Auditors of the Company for the financial year ending 31st March, 2027; and 3. Postal Ballot Notice The requisite disclosure, pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure 'A'. We wish to inform you that the Board Meeting commenced today at 4:30 P.M. and concluded at 5:15 P.M. Kindly take the same on record. Thanking you, FOR MEDICO REMEDIES LIMITED HARESH MEHTA CHAIRMAN & WHOLE-TIME DIRECTOR DIN: 01080289 Encl: As above Annexure-A Disclosure pursuant to Para A of Part A of Schedule Ill of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 Appointment of Cost Auditor Sr. Particulars Disclosure 1 Reason of change viz Appointment of Cost Auditor for FY 2026-27 appointment, resignation, removal, death or otherwise 2 Date of Appointment & Term of Appointment approved in the Board meeting held on 9th November appointment 2026 as Cost Auditor for FY 2026-27 to issue Cost Audit Report as per the provisions of the Companies Act, 2013 3 Brief Profile M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company. Shah Shroff • & Associates Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 ofSEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended THE BOARD OF DIRECTORS MEDICO REMEDIES LIMITED 1105/1106, 11th Floor, Hubtown Solaris Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai -400069 Dear Sirs, Re: Limited Review Report of the Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2026 We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") comprising of profit and loss account, statement ofa ssets and liabilities and statement of cash flow for the half year ended 30th September, 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing Regulations"). This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 09th November, 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to expre~s a conclusion on the statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial lnfonnation perfonned by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that w~ plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. A703, W111Sway Complex, Old Police Linc, Andhcri (E), Mumbai -400 069. Tel: +91-22-6127 7488 / 6697 3268 Email: shahshroff@gnwl.com Shah Shroff • Continuation Sheet & Associates Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Shah Shroff & Associates Chartered Accountants Firm Registration No.: 128920W Partner Number -103277 UDIN: ,J,, 0~1:J-,:t116'DTG 1Cfl Place: Mumbai Date: 09.11.2026